Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’
No Plans To Manufacture, Allocating Capital For Partnerships, Company Tells Generics Bulletin
Joe Azzinaro, Organon’s global commercial leader for biosimilars, sat down to talk with Generics Bulletin about its commercialization expertise and investments for the future.
You may also be interested in...
Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch
Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.
Samsung Bioepis Set To Join High-Concentration Humira Party In Canada
Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.
Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US
Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.